Ysios Capital is a leading Spanish venture capital firm that provides private equity financing to early-stage and emerging growth companies in the life sciences sector. The firm focuses on innovative therapeutic products, diagnostic tests, and medical devices, supporting companies from the development phase to market entry.

Thomas Harth

Joel Jean Mairet

Julia Salaverria

Cristina Garmendia

Ysios Capital

Medical Devices Venture is a holding company that develops a portfolio of investments in Med Tech start-ups. The aim is to combine the expertise of researchers in hospital and university settings with industrialization and commercialization capabilities.

Medical Devices Venture

Seroba Lifesciences is a European life sciences venture capital firm focused on value creation through backing innovations in biotech and medtech.

Seroba Lifesciences

Ysios Capital, a leading Spanish venture capital firm, provides private equity financing to early and mid-stage life science companies that develop disruptive therapeutic products and platform technologies. Founded in 2008, Ysios Capital manages over USD 420M through three dedicated funds in life sciences and is led by a team of professionals experienced in building biotech companies.

BioVex

Aura Biosciences

STAT-Dx

TiGenix

SANIFIT

Prexton Therapeutics

Galecto

Kala Pharmaceuticals

Lava Therapeutics

Mineralys Therapeutics

Minoryx Therapeutics

CVRx

Endosense

#investment I We're proud to share that we have joined a €57M Series A round in Kynexis together with Forbion and Sunstone Life Science Ventures.

🎯 Potential first-in-class #treatment for #cognitiveimpairment associated with #Schizophrenia 

💼 Raúl Martín-Ruiz will be joining the company's Board of Directors.

🔬 The candidate, KYN-5356, is a potent and highly selective KAT-II inhibitor licensed from Mitsubishi Tanabe Pharma Corporation (MTPC). #Funds to advance KYN-5356 toward #clinical development.

The company, co-founded by Forbion and Ysios Capital, has assembled an accomplished leadership #team with decades of experience in #drugdiscovery and development for #neuropsychiatric indications

#vc #biotech ##innovation #mentalhealth #impactinvesting #braindisease

https://lnkd.in/dP4BPh-w

#portfolionews I We're thrilled to share that our #portfolio company in.bio.motion has expanded commercialization of MAF-TEST® to #Africa 👇 

 🤝 Inbiomotion and The Scientific Group sign an exclusive distribution agreement of MAF Test® for the #SubSaharan #Africa

🎯Thanks to this agreement, MAF Test® will now be available in Sub-Saharan Africa and, considering just South Africa, it could increase the survival of 8 out of 10 of the 10,200 early-stage #breastcancer patients diagnosed each year.

👩‍🔬 The MAF-TEST® #predicts the #prognosis of breast cancer patients and helps oncologists to #identify those patients who may be able to #prevent #recurrence and benefit from #adjuvant treatment with #bisphosphonates, which are commonly used to treat osteoporosis. The test also identifies those patients whose prognosis would worsen if treated with bisphosphonates.

#oncology #innovation #vc 
 
https://lnkd.in/dENxSGht

🏆#LifestarsAwards I Congrats CorWave for being named ⭐#Medtech of the year⭐ by the jury of the European Lifestars Awards - Celebrating Life Science eXecutives & their partners

🎯 Developing innovative implantable #blood #pumps based on a #breakthrough membrane technology.
 
#LifestarsAwards #Medtech #LVAD  #vc #ysiosportfolio

#portfolionews I  📌 Excellent news for our #portfolio company in.bio.motion currently commercializing its proprietary MAF-TEST®, a novel tool, backed by level 1B clinical evidence, with the potential to guide #bisphosphonate use in adjuvant breast cancer

 🔝 A team from IRB Barcelona Barcelona led by ICREA researcher Dr. Roger Gomis, co-founder of in.bio.motion, has revealed the mechanism by which the #MAF protein increases the risk of #metastasis in #breastcancer patients. This finding is a crucial step in understanding the molecular basis of metastasis and has relevant clinical implications for treatment.

🔬 The MAF protein interacts with the estrogen receptor, alters its function, and promotes the spread of cancer.

🎯 Results open the possibility of an additional clinical utility of MAF Test®.

🗣 “This study opens the possibility of preventing metastasis by preventing the activation of pro-metastatic genes. This offers new perspectives in the treatment of breast cancer and the clinical utility of MAF-TEST® could be extended to select high-risk patients for extended hormonal therapy and for selecting patients to be included in clinical trials to test the use of new class of drugs -SERDs- in the adjuvant setting as is being carried out by various global pharmaceutical companies.” said Roger Gomis

📑 Full publication here - https://lnkd.in/eDVyFwpU

#MAFTest #oncology #breastcancer #innovation #vc #ysiosportfolio #Spain #Bioregion

https://lnkd.in/dcnY6pYw

Metric
Company Name	Ysios Capital	Medical Devices Venture	Seroba Lifesciences
Symbol
MSH ID	COM:YSIOSCAPITAL	COM:MEDICALDEVICESVENTURE	COM:SEROBA-LIFESCIENCES
Market	PRIVATE	PRIVATE	PRIVATE
Sector	Financial Services & Finance	Healthcare & Health Services	Financial Services & Finance
Industry	Venture Capital	Medical Devices	Venture Capital
Country	ES	FR	IE
Stage
Employee Count	23
Website	ysioscapital.com	medicaldevicesventure.com	seroba-lifesciences.com
LinkedIn	ysios-capital	medical-devices-venture
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic			606
Web Traffic Growth			-0.87
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:YSIOSCAPITAL

Ysios Capital

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue